Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SYRE Spyre Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: SYRE
Price (delayed)
$14.1
Market cap
$850.99M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.04
Enterprise value
$802.49M
aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of
Highlights
SYRE's EPS has soared by 93% YoY and by 4.4% QoQ
The net income has increased by 43% year-on-year
SYRE's revenue has shrunk by 100% YoY
The gross profit has dropped by 100% year-on-year
Key stats
What are the main financial stats of SYRE
Market
Valuations
Earnings
Shares outstanding
60.35M
Market cap
$850.99M
Enterprise value
$802.49M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.76
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$214.36M
Net income
-$208.93M
EBIT
-$208.93M
EBITDA
-$208.93M
Free cash flow
-$169.86M
Per share
Balance sheet
Liquidity
EPS
-$3.04
EPS diluted
-$3.04
Free cash flow per share
-$2.82
Book value per share
$8.01
Revenue per share
$0
TBVPS
$9.45
Total assets
$569.78M
Total liabilities
$87.17M
Debt
$0
Equity
$482.61M
Working capital
$499.09M
Debt to equity
0
Current ratio
8.06
Quick ratio
7.99
Net debt/EBITDA
0.23
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-41.1%
Return on equity
-49.1%
Return on invested capital
-53%
Return on capital employed
-41.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SYRE stock price
How has the Spyre Therapeutics stock price performed over time
Intraday
9.64%
1 week
-6.68%
1 month
5.46%
1 year
-59.93%
YTD
-39.43%
QTD
-12.61%
Financial performance
How have Spyre Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$214.36M
Net income
-$208.93M
Gross margin
N/A
Net margin
N/A
SYRE's revenue has shrunk by 100% YoY
The gross profit has dropped by 100% year-on-year
The net income has increased by 43% year-on-year
Spyre Therapeutics's operating income has increased by 21% YoY but it has decreased by 2.8% QoQ
Price vs fundamentals
How does SYRE's price correlate with its fundamentals
Growth
What is Spyre Therapeutics's growth rate over time
Valuation
What is Spyre Therapeutics stock price valuation
P/E
N/A
P/B
1.76
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
SYRE's EPS has soared by 93% YoY and by 4.4% QoQ
SYRE's P/B is 39% below its last 4 quarters average of 2.9 and 30% below its 5-year quarterly average of 2.5
The company's equity fell by 7% QoQ
SYRE's revenue has shrunk by 100% YoY
Efficiency
How efficient is Spyre Therapeutics business performance
SYRE's return on invested capital has surged by 93% year-on-year and by 15% since the previous quarter
Spyre Therapeutics's ROA has soared by 64% YoY and by 3.5% from the previous quarter
The company's return on equity rose by 19% QoQ
Dividends
What is SYRE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SYRE.
Financial health
How did Spyre Therapeutics financials performed over time
Spyre Therapeutics's quick ratio has decreased by 29% YoY and by 28% QoQ
SYRE's current ratio is down by 29% YoY and by 28% QoQ
Spyre Therapeutics's debt is 100% lower than its equity
The company's equity fell by 7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.